Zoetis Inc. logo

Zoetis Inc. (ZOE)

Market Closed
28 Aug, 20:00
XFRA XFRA
66. 88
+2.36
+3.6578%
- Market Cap
29.76 P/E Ratio
2.12% Div Yield
478 Volume
5.79 Eps
64.52
Previous Close
Add Transaction
Day Range
64.46 66.88
Year Range
61.94 134
Want to track ZOE and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!

Summary

ZOE closed Friday higher at €66.88, an increase of 3.6578% from Thursday's close, completing a monthly increase of 6.8029% or €4.26. Over the past 12 months, ZOE stock lost -38.2342%.
ZOE pays dividends to its shareholders, with the most recent payment made on Jun 02, 2026. The next announced payment will be in In 1 day on Sep 01, 2026 for a total of €0.45977.
The last earnings report, released on Apr 30, 2026, missed the consensus estimates by -1.38%. On average, the company has fell short of earnings expectations by -0.46%, based on the last three reports.
The stock of the company had never split.
The company's stock is traded on 13 different exchanges and in various currencies, with the primary listing on NYSE (USD).

ZOE Chart

Zoetis: A Solid Long-Term Buy After Harsh Drawdown

Zoetis: A Solid Long-Term Buy After Harsh Drawdown

Zoetis is navigating the worst drawdown in its stock history, driven by weakening U.S. vet clinic traffic and heightened competition across key companion animal franchises. Despite aggressive competitor promotions, Zoetis protects industry-leading profitability (35%–37% EBIT margins) using targeted gross-to-net rebates rather than base list-price cuts. Trading at a historic low 12x P/E and a 7%+ FCF yield, Zoetis offers a strong margin of safety compared to its Base Case DCF fair value of $100.06.

Seekingalpha | 1 week ago
Zoetis: Another Bad Quarter, Some Value Trap Risk But Shares Still Cheap

Zoetis: Another Bad Quarter, Some Value Trap Risk But Shares Still Cheap

Zoetis' Q2 earnings results were mixed, and the company cut its forward guidance. This has reduced the stock's margin of safety, but on balance, the risk/reward profile still favors the bulls. Zoetis has other segments performing well which partially offset the weakness in U.S. pet-related sales.

Seekingalpha | 2 weeks ago
Zoetis: The Growth Story Has Broken, But The Valuation Finally Makes Sense

Zoetis: The Growth Story Has Broken, But The Valuation Finally Makes Sense

Zoetis (ZTS) now trades at just 12x forward earnings, with a nearly 3% dividend yield and gross margins above 70%, after a severe multiyear drawdown. Competition, weaker U.S. companion animal sales, and reduced guidance have pressured ZTS, but its core profitability and market dominance remain intact. Management is aggressively repurchasing shares, capital returns are strong, and the balance sheet remains healthy despite $9B in long-term debt.

Seekingalpha | 2 weeks ago

Zoetis Inc. (ZOE) FAQ

What is the stock price today?

The current price is €66.88.

On which exchange is it traded?

Zoetis Inc. is listed on XFRA.

What is its stock symbol?

The ticker symbol is ZOE.

Does it pay dividends? What is the current yield?

Yes, It pays dividends and the current yield is 2.12%.

What is its market cap?

As of today, no market cap data is available.

Has Zoetis Inc. ever had a stock split?

No, there has never been a stock split.

Zoetis Inc. Profile

Specialty Retail Industry
Consumer Discretionary Sector
Kristin C. Peck CEO
XFRA Exchange
98978V103 CUSIP
US Country
14,500 Employees
20 Jul 2026 Last Dividend
- Last Split
1 Feb 2013 IPO Date

Overview

Zoetis Inc. is a global leader in the discovery, development, manufacture, and commercialization of a wide range of animal health medicines, vaccines, and diagnostic products. Founded in 1952 and based in Parsippany, New Jersey, the company addresses the health needs of both livestock—including cattle, swine, poultry, fish, and sheep—and companion animals, such as dogs, cats, and horses. With a presence in both the United States and international markets, Zoetis delivers products and services designed to meet the complex challenges of animal health, ensuring the well-being of animals across the globe. The company's extensive product line-up, alongside innovative diagnostic solutions, makes it a vital player in promoting animal health and supporting the veterinarians, livestock producers, and pet owners who care for them.

Products and Services

Zoetis Inc. offers an expansive portfolio of products and services designed to enhance animal health and support the professionals who work with animals. These include:

  • Vaccines: Zoetis provides biological preparations that protect against diseases of the respiratory, gastrointestinal, and reproductive tracts. These vaccines induce a specific immune response in a variety of animals, helping prevent outbreaks and the spread of infectious diseases in both livestock and companion animals.
  • Anti-infectives: These products are formulated to prevent, kill, or slow the growth of harmful bacteria, fungi, or protozoa. By offering a range of anti-infectives, Zoetis contributes to the overall health and well-being of animals, helping to combat infections before they become widespread issues.
  • Parasiticides: To protect animals from external and internal parasites, Zoetis commercializes treatments that eliminate or prevent infestations such as fleas, ticks, and worms. These products are critical in maintaining animal health and preventing the transmission of parasite-borne diseases to other animals and humans.
  • Other Pharmaceutical Products: Beyond vaccines and parasiticides, Zoetis offers a variety of pharmaceutical products addressing pain and sedation, antiemetic therapies, reproductive health, and oncology in animals. Additionally, the company provides dermatology products for conditions such as allergic dermatitis, ensuring comprehensive care for a wide range of health needs.
  • Medicated Feed Additives: These products mix medicines with livestock feed to prevent or treat disease and enhance overall animal health. Medicated feed additives are a critical component in the maintenance of healthy commercial herds and flocks.
  • Diagnostic Products: Zoetis delivers a variety of diagnostic solutions, including portable blood and urine analysis testing kits, point-of-care products, and instruments. These diagnostic tools are vital for early detection of disease and condition management in animal healthcare settings.
  • Non-Pharmaceutical Products and Services: In addition to its pharmaceutical offerings, Zoetis provides nutritionals and agribusiness services, products for biodevices, genetic tests, and precision animal health solutions. These products and services support the broader aspects of animal care and health management.

Contact Information

Address: 10 Sylvan Way
Phone: 973 822 7000